
Soligenix Reports Extended Positive Phase 2a Results for SGX302 Psoriasis Treatment
Soligenix's extended Phase 2a trial results demonstrate SGX302's continued tolerability and clinical improvements in psoriasis patients using an optimized gel formulation, highlighting its potential as a noncarcinogenic photodynamic therapy.
Read full story























